Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug
Regeneron shares fell 10% due to Eylea sales uncertainty; UCB found bright spots in Alzheimer's drug study; Madrigal's Rezdiffra sales exceeded expectations; AbbVie partnered with EvolveImmune for cancer drugs; another company withdrew a Longboard acquisition offer; FDA to re-evaluate PTC Therapeutics' Translarna for Duchenne muscular dystrophy.
Lessons from the HEALEY adaptive platform trial in amyotrophic lateral sclerosis
S.P. reports research grants and consulting fees from various pharmaceutical companies and organizations. M.C. reports consulting fees and institutional research support from multiple entities and serves on the board of Praxis. B.H. and E.G. report no competing interests.
STAT Summit East – New York City (and virtual) March 20, 2025
George Yancopoulos, M.D., Ph.D., is Board Co-Chair, Co-Founder, President, and Chief Scientific Officer at Regeneron.
Regeneron Reports Third Quarter 2024 Financial and Operating Results
Q3 2024 revenues up 11% to $3.72 billion; Dupixent global net sales by Sanofi up 23% to $3.82 billion; U.S. net sales for EYLEA HD and EYLEA up 3% to $1.54 billion; Libtayo global net sales up 24% to $289 million; GAAP diluted EPS up 30% to $11.54; FDA approves Dupixent for COPD and eosinophilic phenotype; positive results for Dupixent in CSU and BP trials.
Cancer Antibody Drug Conjugates Market, Drugs Approval & Clinical Trials Report 2024
The Cancer Antibody Drug Conjugates Market report highlights the transformative potential of ADCs in cancer treatment, with 16 approved products and sales exceeding $10B in 2023. The market is projected to surpass $50B by 2030, driven by ongoing clinical trials and increased R&D efforts. Key players include Padcev, Kadcyla, and Enhertu, with significant development activity in lung and breast cancer. The market is led by the US and China, with major pharmaceutical companies driving innovation.
Evommune raises $115M to accelerate immune drug tests
Evommune, a California biotech, raised $115 million to advance its two chronic immune condition drugs, EVO756 and EVO301, through Phase 2 trials by 2026. EVO756, an oral treatment targeting mast cells, is in mid-stage testing for chronic skin hives, while EVO301, a fusion protein, aims to treat eczema. The funding, co-led by RA Capital Management and Sectoral Asset Management, positions Evommune for potential IPO.
Market Analysis: AbbVie And Competitors In Biotechnology Industry
AbbVie, a pharmaceutical firm with strong immunology and oncology portfolios, is compared against key competitors in the Biotechnology industry. Analysis reveals AbbVie's PE ratio is low, suggesting potential undervaluation, while its high PB ratio indicates overvaluation based on book value. A low PS ratio implies undervaluation based on sales. AbbVie's high ROE, EBITDA, and gross profit highlight strong profitability and operational efficiency, but low revenue growth indicates challenges in market expansion.
Biomedical Engineering Department celebrates fall 2024 successes
Binghamton University's Biomedical Engineering Department, led by Kaiming Ye and Shelley Dionne, is creating a $1.6 million biomanufacturing project management training program. Ahyeon Koh will research an implantable device for inflammatory disease treatment, while Siyuan Rao advances brain bioelectronics. Sha Jin received a NY state award for upcycling food waste. Qianbin Wang and Siyuan Rao developed a remotely triggered liposomal delivery system for glaucoma. Tracy Hookway researches cardiovascular cells from human skin cells. Student Clara Rodriguez and PhD student Joab Dorsainvil highlight achievements, and a capstone project aims to automate syringe preparation.
AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
Amgen reports Q3 2024 financial results: total revenues up 23% to $8.5 billion, GAAP EPS increased 62% to $5.22, non-GAAP EPS up 13% to $5.58, driven by strong product sales and pipeline investments.
Regeneron loses bid to block Amgen's launch of Eylea biosimilar
Amgen to release biosimilar of Regeneron's Eylea after U.S. appeals court ruling, despite Regeneron's patent infringement claims. Pavblu aims to provide affordable treatment for eye diseases.
© Copyright 2024. All Rights Reserved by MedPath